Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 3Recruiting 2Active not recruiting 2Unknown 1Terminated 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Carcinoma, Non-Small-Cell Lung 85Breast Neoplasms 37Lung Neoplasms 27Triple Negative Breast Neoplasms 25Ovarian Neoplasms 21Squamous Cell Carcinoma of Head and Neck 20Fallopian Tube Neoplasms 16Small Cell Lung Carcinoma 15Neoplasm Metastasis 14Endometrial Neoplasms 13Esophageal Neoplasms 11Neoplasms 10Prostatic Neoplasms 9Colorectal Neoplasms 9Head and Neck Neoplasms 8Carcinoma 8Urinary Bladder Neoplasms 7Uterine Cervical Neoplasms 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Pancreatic Neoplasms 6Oropharyngeal Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Laryngeal Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Squamous Cell 5Stomach Neoplasms 4Mouth Neoplasms 4Melanoma 4Carcinoma, Ovarian Epithelial 4Urothelial Cancer 3

Interventions

Cisplatin 11Gemcitabine 10Radiotherapy, Intensity-Modulated 6Capecitabine 6Drug Therapy 3Docetaxel 3toripalimab 2spartalizumab 2pembrolizumab 2nimotuzumab 2fludarabine 2atezolizumab 2Specimen Handling 2Platinum 2Paclitaxel 2Magnetic Resonance Spectroscopy 2Immunoglobulin G 2Fluorouracil 2Disulfides 2Cyclophosphamide 2Carboplatin 2Bevacizumab 21,2-diaminocyclohexaneplatinum II citrate 2tislelizumab 1sintilimab 1penpulimab 1olaparib 1fludarabine phosphate 1dehydroftorafur 1camrelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Nasopharyngeal Carcinoma × Carboplatin × Clear all
NCT05063552 2026-06-03

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

National Cancer Institute (NCI)

Phase 2/3 Active not recruiting
430 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04974398 2025-04-13

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Akeso

Phase 3 Active not recruiting
296 enrolled 1 FDA
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡